Noel Corporation (CEO Chan-Yang Lim, hereinafter referred to as Noel) is preparing to enter the US market in earnest by introducing its AI-based blood and cancer diagnostic solution, miLab™, at 'CES 2025', the world's largest information technology (IT) and home appliance exhibition, held at the Las Vegas Convention Center (LVCC) from the 7th to the 10th.
Noel CEO Chan-Yang Lim said, “Through our participation in CES 2025, we plan to introduce MyLab’s innovative technology to the US market and actively explore possibilities for collaboration with major medical institutions in the US.” He added, “We are currently taking steps to fully enter the US market for MyLab, and based on this, we will provide products optimized for the local medical environment in the US, leading new innovation in the digital healthcare market.”
During the exhibition, Noel will operate a booth in the Korea Pavilion, the largest-ever integrated exhibition hall, featuring 36 organizations and 445 companies. On the first day of the exhibition, approximately 100 participants, including global healthcare and technology professionals, partners, investors, analysts, media representatives, and visitors, visited the Noel booth and showed keen interest in MyLab's innovative diagnostic technology. They were particularly interested in MyLab's product concept, which enables point-of-care diagnosis in major countries such as North America, Europe, and Korea. Many questions were also raised about MyLab's future cancer product lineup, including its cervical cancer product.
At CES 2025, keynote speeches from leading industry companies discussed the systemic changes and trends AI will bring. NVIDIA CEO Jensen Huang predicted that robotics will usher in the future of AI, while major healthcare companies, including Google and Abbott, emphasized that AI technology is shifting the focus of healthcare from disease treatment to well-being.
Noel's MyLab is a first-in-class blood and cancer diagnostic solution that combines robotics, medical AI, and biotechnology. Noel, which possesses robotics technology optimized for digital healthcare medical devices, developed MyLab, which will change the paradigm of microscopic diagnosis, which has been performed by hand for over 100 years. MyLab is an innovative medical device that fully automates the entire diagnostic process, from specimen staining to imaging and AI analysis. Furthermore, it is characterized by implementing diagnostic accuracy and high convenience comparable to large diagnostic labs in the field through on-device AI equipped with NVIDIA edge computing technology.
Meanwhile, Noel has completed registration of four of its medical devices (miLab™ Platform, miLab™ Cartridge MAL, miLab™ Cartridge BCM, and SafeFix™) with the US FDA as Class 1 medical devices. This is a preliminary step toward signing a contract with a US client, which is currently under discussion. Noel is currently pursuing FDA approval for each of its miLab solutions, step by step, to fully enter the US market.
The Consumer Electronics Show (CES) is the world's largest technology and home appliance exhibition, attracting over 4,500 companies and 180,000 attendees from approximately 170 countries. It offers a glimpse into future technological innovations across diverse fields, including AI, digital healthcare, mobility, and smart homes. CES 2025, in particular, focused on the theme of "A New Innovation Paradigm in the AI Era," with AI as a key topic.
- See more related articles
You must be logged in to post a comment.